Drug Profile


Alternative Names: GTx-024; MK-2866; Ostarine; S-22

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GTx
  • Developer City of Hope National Medical Center; GTx; National Cancer Institute (USA)
  • Class Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase II Breast cancer; Stress incontinence
  • Preclinical Duchenne muscular dystrophy
  • Discontinued Cachexia; Muscular atrophy

Most Recent Events

  • 14 Nov 2017 Interim data from a phase II trial in Breast cancer released by GTx
  • 25 Sep 2017 GTx terminates a phase II trial for Breast cancer (Second-line therapy or greater, Metastatic disease) due to lack of efficacy in Lithuania and USA (PO) (NCT02368691)
  • 13 Sep 2017 Additional efficacy and adverse events data from a proof-of-concept phase II trial in Stress incontinence released by GTx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top